Sitagliptin Phosphate and Metformin Hydrochloride 50 mg; 500 mg Tablet, Film Coated, Extended Release, 21,405-count — NDC 66406-0325-0 (Billing 66406-0325-00)
This is a package of 21,405 tablets of Sitagliptin Phosphate and Metformin Hydrochloride 50 mg; 500 mg Tablet, Film Coated, Extended Release from Patheon Inc., marketed since Feb 2012 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 66406-0325-0 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 66406 labeler · 0325 product · 0 package
- Package marketed since
- Feb 2, 2012
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 6640603250 3
- FDA record last changed
- Aug 20, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
This is an extended-release film-coated tablet combining two oral diabetes medicines. Metformin hydrochloride is typically used to help control blood sugar levels in type 2 diabetes. Sitagliptin phosphate works by a different mechanism and is also commonly used to help manage blood sugar in type 2 diabetes. The combination allows both active ingredients to be taken in a single dose.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 7, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 66406-0325-00 You're viewing this Main listing | 21405 TABLET, FILM COATED, EXTENDED RELEASE in 1 CONTAINER | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| SITAGLIPTIN PHOSPHATE and METFORMIN HYDROCHLORIDE 50 mg/1; 500 mgthis 66406-0325-00 | Patheon | 21405 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Patheon Inc. labeler code 66406
- atazanavir sulfate 300 mg Capsule, Gelatin Coated NDC 66406-0288-0
- atazanavir sulfate and cobicistat 300 mg; 150 mg Tablet NDC 66406-0289-0
- lumateperone 42 mg Capsule NDC 66406-0300-0
- Voxelotor 500 mg Tablet, Film Coated NDC 66406-0301-0
- Sitagliptin Phosphate and Metformin Hydrochloride 50 mg; 1000 mg Tablet, Film Coated, Extended Release NDC 66406-0323-0
- Sitagliptin Phosphate and Metformin Hydrochloride 100 mg; 1000 mg Tablet, Film Coated, Extended Release NDC 66406-0324-0
- eslicarbazepine acetate 400 mg Tablet NDC 66406-0327-0
- entecavir .05 mg/mL Solution NDC 66406-0331-0
- molnupiravir 200 mg Capsule NDC 66406-0332-0
- voxelotor 300 mg Tablet, For Suspension NDC 66406-0333-0
- Oteseconazole 150 mg Capsule, Gelatin Coated NDC 66406-0334-0
- Dextromethorphan Hydrobromide and Bupropion Hydrochloride 45 mg; 105 mg Tablet, Multilayer, Extended Release NDC 66406-0336-0
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Patheon Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |